nct_id: NCT05967689
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-08-01'
study_start_date: '2023-07-31'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: TAS6417'
  - drug_name: 'Drug: Transporter Cocktail'
  - drug_name: 'Drug: CYP Cocktail'
long_title: An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the
  Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic
  Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound
  Epidermal Growth Factor Receptor Mutations.
last_updated: '2025-10-02'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Taiho Oncology, Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 224
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. Written informed consent.
- "2. \u226518 years of age (or meets the country's regulatory definition of legal\
  \ adult age, whichever is greater."
- '3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the
  following criteria:'
- 'Cohort A participants:'
- '* Documented EGFR ex20ins status, as determined by local testing performed at a
  Clinical Laboratory Improvement Amendments (CLIA) certified (United States \[US\])
  or locally certified laboratory (outside the US).'
- '* Progressed on or after systemic therapy with an agent targeting ex20ins, either
  alone or in combination with standard platinum-based chemotherapy for the treatment
  of advanced disease. Participants who discontinued previous treatment due to unacceptable
  toxicity are eligible.'
- 'i. Permitted prior ex20ins therapies include: amivantamab, sunvozertinib (DZD9008),
  and BLU451. Other prior ex20ins--directed treatment may be discussed with the Sponsor
  for eligibility assessment.'
- '* Participants with brain metastasis must be neurologically stable. Participants
  must have received central nervous system (CNS)-directed therapy and have no evidence
  of progression for at least 4 weeks after CNS-directed treatment, as ascertained
  by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or
  computed tomography \[CT\] scan) during the Screening Period. Additionally, they
  must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant
  medications for at least 2 weeks prior to the first dose of study treatment. Participants
  with a history of uncontrolled seizures or LMD are not eligible.'
- 'Cohort B participants:'
- '* Documented EGFR ex20instatus, as determined by local testing performed at a CLIA-certified
  (US) or locally certified laboratory (outside the US).'
- '* Participants who have not received prior treatment for advanced or metastatic
  disease and who are not appropriate candidates for first-line doublet platinum-based
  chemotherapy based on Investigator judgment or has refused first-line doublet platinum-based
  chemotherapy following discussion with the Investigator. Prior adjuvant/neoadjuvant
  treatment for early-stage disease must have been completed \>6 months prior to the
  first dose of study treatment.'
- '* Participants with brain metastasis must be neurologically stable. Participants
  must have received CNS-directed therapy and have no evidence of progression for
  at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination
  and brain imaging (MRI or CT scan) during the Screening Period, and they must be
  on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications
  for at least 2 weeks prior to the first dose of study treatment. Participants with
  history of uncontrolled seizures or LMD are not eligible.'
- 'Cohort C participants:'
- '* Documented ex20ins or other uncommon single or compound EGFR non-ex20ins status,
  as determined by local testing performed at a CLIA-certified (US) or locally certified
  laboratory (outside the US).'
- '* Presence of brain metastasis(es) characterized as at least one of the following:'
- '* Newly diagnosed and/or progressive brain metastasis(es) measurable by Response
  Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteria and not subjected
  to CNS-directed therapy, AND/OR'
- '* LMD measurable or non-measurable by RANO-BM criteria and confirmed by a positive
  cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.'
- '* Participants may not require other immediate CNS-directed therapy or will likely
  require other CNS directed anti-tumor therapy during the first cycle of study treatment,
  as judged by the Investigator.'
- 'Cohort D participants:'
- '* Documented other uncommon single or compound EGFR non-ex20ins status (excluding
  C797S), as determined by local testing performed at a CLIA certified (US) or locally
  certified laboratory (outside the US). A list of eligible mutations will be provided
  in a separate document.'
- '* Participants with brain metastasis must be neurologically stable. Participants
  must have received CNS-directed therapy and have no evidence of progression for
  at least 4 weeks after CNS- directed treatment, as ascertained by clinical examination
  and brain imaging (MRI or CT scan) during the Screening Period, and they must be
  on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications
  for at least 2 weeks prior to the first dose of study treatment. Participants with
  history of uncontrolled seizures or LMD are not eligible.'
- '* Participants who have not received prior systemic therapy for their locally advanced
  or metastatic NSCLC disease.'
- '* Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed
  \>6 months prior to the first dose of study treatment. Participants may not have
  received prior adjuvant/neoadjuvant treatment with any EGFR tyrosine kinase inhibitor
  (TKI).'
- 4. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1
  (RECIST 1.1).
- 5. Archival tumor tissue available for submission, with minimum quantity sufficient
  to evaluate EGFRmt status and, where possible, other biomarkers (details provided
  in a laboratory manual). Participants with insufficient tissue may be eligible following
  discussion with the Sponsor.
- 6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17.
- 7. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory
  values.
- 8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy
  test prior to administration of the first dose of study treatment. Female participants
  are not considered to be of childbearing potential if they are post-menopausal (no
  menses for 12 months without an alternative medical cause) or permanently sterile
  (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
- 9. Both males and females of reproductive potential must agree to use effective
  birth control during the study prior to the first dose of study drug and for 1 month
  after the last dose of study treatment.
- 'DDI Substudy:'
- '1. Participant has pathologically confirmed, locally advanced or metastatic NSCLC:'
- 'a. Documented EGFRmt status as determined by local testing performed at a clinical
  laboratory improvement amendments (CLIA) certified (US) or locally certified laboratory
  (outside of the US) local laboratory, defined as either one of the following EGFRmts:'
- '* ex20ins EGFRmt OR'
- '* other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) OR'
- '* common EGFRmt (eg, ex19del or L858R)'
- '2. Participant has progressed on or after receiving prior standard of care (SoC)
  systemic therapy for their locally advanced or metastatic NSCLC disease unless:'
- '* Participant for whom no approved therapy with demonstrated clinical benefit is
  indicated or available,'
- '* Participant is intolerant to the available first-line (1L) SoC treatment options,
  OR'
- '* Participant has refused 1L SoC treatment options (after being appropriately informed
  of the treatment options, risks, and benefits).'
- '3. Participants with brain metastasis are eligible if they fulfill all of the criteria
  below:'
- '* Have received CNS-directed therapy and have no evidence of progression for at
  least 4 weeks after CNS- directed treatment, as ascertained by brain imaging (MRI
  or CT scan) during the Screening Period,'
- '* Are on a stable or decreasing dose of corticosteroids and/or anti-convulsant
  medications for at least 2 weeks prior to the first dose of study treatment,'
- '* Are neurologically stable with no history of uncontrolled seizures.'
- 4. ECOG PS of 0 or 1.
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. Participant is currently receiving an investigational drug in a clinical
  trial or participating in any other type of medical research judged to be scientifically
  or medically incompatible with this study.
- 'Exclude - 2. Has received any of the following within the specific time frame specified:'
- Exclude - 1. Participant has received Zipalertinib (TAS6417/CLN081) at any time
- "Exclude - 2. Thoracic radiotherapy \u226428 days or palliative radiation (gamma\
  \ knife radiotherapy is allowed) \u226414 days prior to the first dose of study\
  \ treatment"
- "Exclude - 3. Anticancer immunotherapy \u226428 days prior to the first dose of\
  \ study treatment"
- "Exclude - 4. Major surgery (excluding placement of vascular access) \u226428 days\
  \ prior to the first dose of study treatment."
- Exclude - 5. All prescribed medication, over-the-counter medication, vitamin preparations
  and other food supplements, or herbal medications that are strong or moderate CYP3A4
  inducers or inhibitors within 7 days prior to first dose of study treatment
- "Exclude - 3. Have any unresolved toxicity of Grade \u22652 from previous anticancer\
  \ treatment, except for Grade 2 alopecia or skin pigmentation. Participants with\
  \ other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement\
  \ between the Investigator and Sponsor."
- Exclude - 4. Past medical history of interstitial lung disease, treatment-related
  pneumonitis (any grade), or evidence of clinically active interstitial lung disease.
- 'Exclude - 5. Impaired cardiac function or clinically significant cardiac disease
  including any of the following:'
- Exclude - 1. History of congestive heart failure (CHF) Class III/IV according to
  the New York Heart Association (NYHA) Functional Classification.
- Exclude - 2. Serious cardiac arrhythmias requiring treatment.
- Exclude - 3. Resting corrected QT interval (QTc) \>470 msec using Fridericia's formula
  (QTcF).
- Exclude - 6. Is unable to swallow tablets or has any disease or condition that may
  significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory
  bowel disease, malabsorption syndrome, or prior gastric/bowel resection).
- "Exclude - 7. History of another primary malignancy \u22642 years prior to the date\
  \ of first dose of study treatment unless at least one of the following criteria\
  \ are met:"
- Exclude - 1. Adequately treated basal or squamous cell carcinoma of the skin
- Exclude - 2. Cancer of the breast or cervix in situ
- Exclude - 3. Participants with previously treated malignancy if all treatment for
  that malignancy was completed at least 2 years prior to first dose and no evidence
  of disease
- Exclude - 4. Participants with concurrent malignancy clinically stable and not requiring
  tumor-directed treatment
- Exclude - 8. Known history of hepatitis B, hepatitis C, or human immunodeficiency
  virus (HIV) that is not controlled with treatment.
- Exclude - 9. History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks
  prior to enrollment and/or has persistent clinically significant pulmonary symptoms
  related to prior COVID-19 infection.
- Exclude - 10. Active bleeding disorders.
- Exclude - 11. Known hypersensitivity to the ingredients in zipalertinib or any drugs
  similar in structure or class.
- Exclude - 12. Is pregnant, lactating, or planning to become pregnant.
- Exclude - 13. The participant is, in the Investigator's opinion, unable or unwilling
  to comply with the trial procedures.
- Exclude - 14. Any other clinically significant acute or chronic medical or psychiatric
  condition that may increase the risk associated with study drug administration,
  or may interfere with the interpretation of substudy results based on Investigator
  discretion.
short_title: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung
  Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other
  Uncommon Mutation.
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Taiho Oncology, Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics
  (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small
  Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Cohort A ("prior ex20ins treatment")
      arm_internal_id: 0
      arm_description: Cohort A ("prior ex20ins treatment") participants will receive
        zipalertinib orally twice a day (BID) continuously until documentation of
        progressive disease (PD) or until other withdrawal criteria are met, whichever
        comes first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TAS6417'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Cohort B ("first-line treatment")
      arm_internal_id: 1
      arm_description: Cohort B participants will receive zipalertinib orally, BID
        continuously until documentation of PD or until other withdrawal criteria
        are met, whichever comes first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TAS6417'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Cohort C ("active brain mets")
      arm_internal_id: 2
      arm_description: Cohort C participants will receive zipalertinib orally, BID
        continuously until documentation of PD or until other withdrawal criteria
        are met, whichever comes first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TAS6417'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Cohort D ("other uncommon EGFRmts").
      arm_internal_id: 3
      arm_description: Cohort D participants will receive zipalertinib orally, BID
        continuously until documentation of PD or until other withdrawal criteria
        are met, whichever comes first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TAS6417'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'DDI Substudy: CYP Cocktail Group'
      arm_internal_id: 4
      arm_description: Participants will receive a single dose of CYP enzyme probe
        substrates (CYP cocktail) alone prior to the start of zipalertinib dosing
        and a single dose of CYP cocktail in combination with zipalertinib at steady
        state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21
        days), followed by continuous treatment with zipalertinib until documentation
        of PD or until other withdrawal criteria are met, whichever comes first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TAS6417'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: CYP Cocktail'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'DDI Substudy: Transporter Cocktail Group'
      arm_internal_id: 5
      arm_description: Participants will receive a single dose of transporter probe
        substrates (Transporter cocktail) alone prior to the start of zipalertinib
        dosing and a single dose of Transporter cocktail in combination with zipalertinib
        at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle
        length = 21 days), followed by continuous treatment with zipalertinib until
        documentation of PD or until other withdrawal criteria are met, whichever
        comes first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TAS6417'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Transporter Cocktail'
        level_internal_id: 1
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Locally Advanced
          - Metastatic
          oncotree_primary_diagnosis: Non-Small Cell Lung Cancer
      - or:
        - genomic:
            hugo_symbol: EGFR
            variant_category: Mutation
